FDA has granted accelerated approval for Replimune’s oncolytic viral therapy, Tudriqev, for advanced melanoma after the program returned from an earlier FDA rejection and a swift resubmission cycle. The decision follows a positive advisory committee vote and positions Tudriqev as a more convenient alternative to cell therapies already used in the setting, according to the coverage. The approval marks another high-speed pathway outcome for companies developing immune-activating viral platforms, while also underscoring how FDA scrutiny can rapidly change a development path—from rejection to accelerated authorization—within a short window.